uniQure director exercises options and sells 10K shares

uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares.

Rhea-AI Filing Summary

uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. He exercised stock options for 10,000 shares at $8.49 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $27.85 per share. After these transactions, he directly holds 43,254 Ordinary Shares. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026, and that the sale prices ranged from $27.58 to $28.05.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($194K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Balachandran Madhavan

Role Director

Sold 10,000 shs ($279K)

Approx. gross sale proceeds $279K

Approx. exercise cost $85K

Approx. pre-tax spread $194K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Ordinary Shares	10,000	$8.49	$85K
Sale	Ordinary Shares	10,000	$27.85	$279K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Ordinary Shares — 43,254 shares (Direct)

Footnotes (3)

1. F1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.05. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
3. F3. The Stock Option vested in full on September 20, 2021.

Key Figures

Shares sold: 10,000 shares Sale price: $27.85/share Options exercised: 10,000 shares +3 more

6 metrics

Shares sold 10,000 shares Open-market sale of Ordinary Shares at weighted average $27.85

Sale price $27.85/share Weighted average sale price; trades from $27.58 to $28.05

Options exercised 10,000 shares Stock Option (Right to Buy) for Ordinary Shares

Exercise price $8.49/share Exercise price of Stock Option converted into Ordinary Shares

Shares held after 43,254 shares Direct Ordinary Share holdings following the reported transactions

Option expiration September 20, 2027 Expiration date of the 10,000-share Stock Option

Key Terms

Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Ordinary Shares

4 terms

Rule 10b5-1 regulatory

"intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Ordinary Shares financial

"security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did uniQure (QURE) director Balachandran Madhavan report?

Balachandran Madhavan reported exercising stock options for 10,000 uniQure Ordinary Shares and selling 10,000 shares in an open-market transaction. These combined actions left his direct holdings at 43,254 Ordinary Shares after the transactions disclosed in the Form 4.

At what prices did Balachandran Madhavan trade uniQure (QURE) shares?

He exercised options at an exercise price of $8.49 per share and sold 10,000 Ordinary Shares at a weighted average price of $27.85. The sale occurred in multiple trades with prices ranging from $27.58 to $28.05 per share.

How many uniQure (QURE) shares does Balachandran Madhavan hold after the Form 4 transactions?

Following the reported option exercise and share sale, Balachandran Madhavan directly holds 43,254 uniQure Ordinary Shares. This figure reflects his position after exercising 10,000 options and selling 10,000 shares in an open-market transaction on the reported transaction date.

Were the uniQure (QURE) insider sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the reported transactions were executed under a sales plan adopted on March 10, 2026 and intended to comply with Rule 10b5-1. Such pre-arranged plans schedule trades in advance under predetermined instructions.

What stock option details are disclosed in the uniQure (QURE) Form 4 filing?

The filing shows a Stock Option for 10,000 Ordinary Shares with an exercise price of $8.49 per share. The option vested in full on September 20, 2021 and has an expiration date of September 20, 2027, with 10,000 shares exercised in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 05:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balachandran Madhavan

(Last) (First) (Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM 1105BP

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/15/2026		M(1)		10,000	A	$8.49	53,254	D
Ordinary Shares	06/15/2026		S(1)		10,000	D	$27.85(2)	43,254	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.49	06/15/2026		M(1)			10,000	(3)	09/20/2027	Ordinary Shares	10,000	$0	0	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.05. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

3. The Stock Option vested in full on September 20, 2021.

	/s/ Christian Klemt, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)